The company completes its enrolment in phase 3 trial evaluating ensifentrine for treatment of COPD
News
Ziphius Vaccines and University of Antwerp begin collaboration
The partnership will involve the optimised delivery of saRNA-based vaccines and therapeutics
Coave Therapeutics and ABL link up to develop gene therapy manufacturing processes
Agreement between the two companies includes process development of AAV-based gene therapies
Takeda’s dengue vaccine candidate delivers continued protection
Vital dengue vaccine offers over four years’ protection following successful clinical trial
Innovation Passport awarded Alnylam and its hypertension therapy
The company received the Innovation Passport in the UK for zilebesiran, an investigational treatment of hypertension
Westminster Drug Project and Gilead Sciences join forces to take on hepatitis C
The companies have partnered for a second time to support sector-wide efforts to eliminate hepatitis C virus in drug and alcohol services
Bachem and Eli Lilly link up to advance oligonucleotide products
The agreement will see the two companies expand current oligonucleotide technologies
Vertex trial for hypoglycaemia therapy shows early promise
New data now reveals significant increases in the blood glucose time-in-range compared to baseline, following VX-880 dosage
2022 Marketer of the Year competition has launched!
Celebrating and uncovering exceptional pharma marketing talent for nearly three decades, the 2022 Marketer of the Year competition has launched!
The PharmaTimes Communications Awards are back for 2022!
Unique to the industry, the Communications Awards gives the opportunity for communications professionals to demonstrate their leadership, creativity, and teamwork skills in a variety of fun and engaging virtual challenges.
Daiichi Sankyo and AstraZeneca’s Enhertu delivers promising trial results
Enhertu reduced the risk of disease progression or death compared to chemotherapy in certain patients with metastatic breast cancer
Cambridge Pharma promises to boost drug development
New facility opens on the Cambridge Research Park offering sterile finish
Teva UK introduces first generic oral anticoagulant
Apixaban will be available for the prevention of stroke and deep vein thrombosis
NICE recommends UCB’s Fintepla for Dravet syndrome
The drug is used to treat seizures caused by this rare syndrome that is a form of epilepsy
Sandoz launches new global health inequalities initiative
‘Act4Biosimilars’ will improve patient access and increase adoption in over 30 countries by 2030
